Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice

Journal of Immunotherapy

Volumn 28, Issue 5, 2005, Pages 449-460

  Johnson, Bryon D ^a   Gershan, Jill A ^a   Natalia, Natalia ^a   Zujewski, Heidi ^a   Weber, James J ^a   Yan, Xiaocai ^a   Orentas, Rimas J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Plasmid vectors; T cells; Tumor immunity; Vaccination

Indexed keywords

B7 ANTIGEN; CD137 LIGAND; CD86 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSFECTION; IMMUNE RESPONSE; MOUSE; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TIME SERIES ANALYSIS; TUMOR CELL LINE;

EID: 24144487135     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000171313.93299.74     Document Type: Article

References (39)

1. Johnson BD, Yan X, Schauer DW, et al. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol. 2003;222:15-26.
2. Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology. 2004;112:105-116.
3. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228:307-319.
4. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949.
5. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998;9:1303-1311.
6. Hellstrom IE, Hellstrom KE, Pierce GE, et al. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci USA. 1968;60:1231-1238.
7. Bill AH. The implications of immune reactions to neuroblastoma. Surgery. 1969;66:415-418.
8. Evans AE, Hummeler K. The significance of primitive cells in marrow aspirates of children with neuroblastoma. Cancer. 1973;32:906-912.
9. Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg. 1968;3:161-164.
10. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
11. Handgretinger R, Leung W, Ihm K, et al. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer. 2003;88:1874-1877.
12. Sanburn N, Cornetta K. Rapid titer determination using quantitative real-time PCR. Gene Ther. 1999;6:1340-1345.
13. Orentas RJ, Schauer D, Bin Q, et al. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol. 2001;213:4-13.
14. Trompeter HI, Weinhold S, Thiel C, et al. Rapid and highly efficient gene transfer into natural killer cells by nucleofection. J Immunol Methods. 2003;274:245-256.
15. Martinet W, Schrijvers DM, Kockx MM. Nucleofection as an efficient nonviral transfection method for human monocytic cells. Biotechnol Lett. 2003;25:1025-1029.
16. Lai W, Chang CH, Farber DL. Gene transfection and expression in resting and activated murine CD4 T cell subsets. J Immunol Methods. 2003;282:93-102.
17. Schakowski F, Buttgereit P, Mazur M, et al. Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther. 2004;2:1.
18. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta. 1995;1235:296-304.
19. Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995;270:18997- 19007.
20. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;35:5616-5623.
21. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92:7297-7301.
22. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci USA. 1999;96:5177-5181.
23. Katsanis E, Orchard PJ, Bausero MA. et al. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother Emphasis Tumor Immunol. 1994;15:81-90.
24. Hock RA, Reynolds BD, Tucker-McClung CL, et al. Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. J Immunother Emphasis Tumor Immunol. 1995;17:12-18.
25. Katsanis E, Bausero MA, Xu H, et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother. 1994;38:135-141.
26. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer. 2003;88:1641-1648.
27. Bausero MA, Panoskaltsis-Mortari A, Blazar BR, et al. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. J Immunother Emphasis Tumor Immunol. 1996;19:113-124.
28. Heuer JG, Tucker-McClung C, Gonin R, et al. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. Hum Gene Ther. 1996;7:2059-2068.
29. Haight AE, Bowman LC, Ng CY, et al. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med Pediatr Oncol. 2000;35:712-715.
30. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101:1718-1726.
31. Cooper D, Bansal-Pakala P, Croft M.4-1BB (CD137) controls the clonai expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol. 2002;32:521-529.
32. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-760.
33. Auf G, Chen L, Fornes P, et al. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett. 2002;327:189-192.
34. Sandler AD, Chihara H, Kobayashi G, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003;63:394-399.
35. Andrews JM, Newbound GC, Lairmore MD. Transcriptional modulation of viral reporter gene constructs following induction of the cellular stress response. Nucleic Acids Res. 1997;25:1082-1084.
36. Welch WJ, Kang HS, Beckmann RP, et al. Response of mammalian cells to metabolic stress; changes in cell physiology and structure/function of stress proteins. In: Kaufmann SHE, ed. Current Topics in Microbiology and Immunology. Vol 167. Berlin. Heidelberg: Springer-Verlag; 1991:31-55.
37. Liu B, DeFilippo AM, Li Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol Cancer Ther. 2002;1:1147-1151.
38. Prohaszka Z, Fust G. Immunological aspects of heat-shock proteins: the optimum stress of life. Mol Immunol. 2004;41:29-44.
39. Schakowski F, Gorschluter M, Junghans C, et al. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther. 2001;3:793-800.